Top

Published in:

Open Access 01-12-2016 | Clinical trial

Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study

Authors: M. E. Cazzaniga, L. Cortesi, A. Ferzi, L. Scaltriti, F. Cicchiello, M. Ciccarese, S. Della Torre, F. Villa, M. Giordano, C. Verusio, M. Nicolini, A. R. Gambaro, L. Zanlorenzi, E. Biraghi, L. Legramandi, E. Rulli, On behalf of VICTOR Study Group

Published in: Breast Cancer Research and Treatment | Issue 3/2016

Abstract

Purpose

The VICTOR-1 study demonstrated that the all-oral metronomic combination of vinorelbine and capecitabine is highly active and well tolerated in hormone receptor-positive/HER2-negative patients. The VICTOR-2 study was designed to confirm these results.

Methods

Patients received mVNR 40 mg three times a week and mCAPE 500 mg three times a day, continuously. The primary endpoint was the clinical benefit rate (CBR); secondary endpoints were toxicity, objective response rate (ORR), and progression-free survival (PFS).

Results

Eighty patients were evaluable for the primary efficacy analysis. Median age was 65.3 years; most patients had HR-positive tumors (65 %). The CBR was 45.7 % (95 % CI 28.8–63.4) and 51.1 % (95 % CI 35.8–66.3) in first- and ≥ second-line therapy, respectively. The ORR was 35.5 % in first-line (95 % CI 19.2–54.6) and 25.6 % in ≥second-line (95 % CI 13.5–41.2). The median duration of response was 11.3 and 6.4 months and PFS rates at 1 year were 24.3 and 22.2 %, respectively. In triple-negative breast cancer patients (N = 28, 35 %) a lower, but clinically relevant CBR (35.7, 95 % CI 18.6–55.9) was observed. The main toxicities per cycle were non-febrile neutropenia (1.1 %), hand-foot syndrome (1.0 %), nausea and vomiting (1.0 %), leucopenia (0.8 %), fatigue (0.7 %), and diarrhea (0.4 %).

Conclusion

The VICTOR-2 study confirms the clinical activity of mVNR and mCAPE in HER2-negative breast cancer patients, suggesting that the easy schedule of administration, which requires monthly blood tests and limits patients’ dependence on hospitals, and the low cost of the drugs are valuable elements, even for countries with limited access to innovative or expensive drugs.

Available only for authorised users

Cazzaniga ME, Camerini A, Addeo R et al (2016) Metronomic oral vinorelbine in advanced breast cancer and non-small-cell lung cancer: current status and future development. Futur Oncol 12:373–378CrossRef

Di Desidero T, Xu P, Man S et al (2015) Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer. Oncotarget 6:42396–42410PubMedPubMedCentral

Kareva I, Waxman DJ, Lakka Klement G (2015) Metronomic chemotherapy: an attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance. Cancer Lett 358:100–106CrossRefPubMed

Cazzaniga ME, Torri V, Villa F et al (2014) Efficacy and safety of the all-oral schedule of metronomic vinorelbine and capecitabine in locally advanced or metastatic breast cancer patients: the phase I-II VICTOR-1 study. Int J Breast Cancer 2014:769790CrossRefPubMedPubMedCentral

Montagna E, Lai A, Palazzo A et al (2015) A phase II study of metronomic oral chemotherapy for metastatic breast cancer patients: Safety and efficacy results of vinorelbine, cyclophosphamide plus capecitabine (VEX) combination. Eur J Cancer Congr 51:S291–S292CrossRef

Addeo R, Sperlongano P, Montella L et al (2012) Protracted low dose of oral vinorelbine and temozolomide with whole-brain radiotherapy in the treatment for breast cancer patients with brain metastases. Cancer Chemother Pharmacol 70:603–609CrossRefPubMed

Saloustros E, Kalbakis K, Vardakis N et al (2011) Metronomic vinorelbine plus bevacizumab as salvage therapy for patients with metastatic breast cancer. J BUON 16:215–218PubMed

De Iuliis F, Salerno G, Taglieri L et al (2015) On and off metronomic oral vinorelbine in elderly women with advanced breast cancer. Tumori J 101:30–35CrossRef

Tubiana-Mathieu N, Bougnoux P et al (2009) All-oral combination of oral vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer: an International Phase II trial. Br J Cancer 101:232–237CrossRefPubMedPubMedCentral

10.

Nolè F, Crivellari D, Mattioli R et al (2009) Phase II study of an all-oral combination of vinorelbine with capecitabine in patients with metastatic breast cancer. Cancer Chemother Pharmacol 64:673–680CrossRefPubMed

11.

A’Hern RP (2001) Sample size tables for exact single-stage phase II designs. Stat Med 20:859–866CrossRefPubMed

12.

Colleoni M, Rocca A, Sandri MT et al (2002) Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol 13:73–80CrossRefPubMed

13.

Orlando L, Cardillo A, Ghisini R et al (2006) Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer. BMC Cancer 6:225CrossRefPubMedPubMedCentral

14.

Wang Z, Lu J, Leaw S et al (2012) An all-oral combination of metronomic cyclophosphamide plus capecitabine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: a phase II study. Cancer Chemother Pharmacol 69:515–522CrossRefPubMed

15.

Addeo R, Sgambato A, Cennamo G et al (2010) Low-dose metronomic oral administration of vinorelbine in the first-line treatment of elderly patients with metastatic breast cancer. Clin Breast Cancer 10:301–306CrossRefPubMed

16.

Gennari A, Stockler M, Puntoni M et al (2011) Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials. J Clin Oncol 29:2144–2149CrossRefPubMed

17.

Lien K, Georgsdottir S, Sivanathan L et al (2013) Low-dose metronomic chemotherapy: a systematic literature analysis. Eur J Cancer 49:3387–3395CrossRefPubMed

Title: Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study
Authors: M. E. Cazzaniga
L. Cortesi
A. Ferzi
L. Scaltriti
F. Cicchiello
M. Ciccarese
S. Della Torre
F. Villa
M. Giordano
C. Verusio
M. Nicolini
A. R. Gambaro
L. Zanlorenzi
E. Biraghi
L. Legramandi
E. Rulli
On behalf of VICTOR Study Group
Publication date: 01-12-2016
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 3/2016
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-016-4009-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2016

miRpower: a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients

Platinum salts in advanced breast cancer: a systematic review and meta-analysis of randomized clinical trials

Characterization of a novel germline PALB2 duplication in a hereditary breast and ovarian cancer family

Outcomes of patients with inflammatory breast cancer treated by breast-conserving surgery

Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care

Circulating tumor cells in breast cancer: applications in personalized medicine

Keynote webinar | Spotlight on antibody–drug conjugates in cancer